[HTML][HTML] Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities
X Zhang, T Wu, X Cai, J Dong, C Xia, Y Zhou… - Frontiers in …, 2022 - frontiersin.org
Patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence
and metastasis, although neoadjuvant therapy may provide some benefit. However, patients …
and metastasis, although neoadjuvant therapy may provide some benefit. However, patients …
Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
X Zhang, T Wu, X Cai, J Dong, C Xia… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence
and metastasis, although neoadjuvant therapy may provide some benefit. However, patients …
and metastasis, although neoadjuvant therapy may provide some benefit. However, patients …
Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
X Zhang, T Wu, X Cai, J Dong, C Xia, Y Zhou… - Frontiers in …, 2022 - europepmc.org
Patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence
and metastasis, although neoadjuvant therapy may provide some benefit. However, patients …
and metastasis, although neoadjuvant therapy may provide some benefit. However, patients …
Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
X Zhang, T Wu, X Cai, J Dong, C Xia… - … inhibitors for non …, 2022 - books.google.com
Global cancer statistics for 2020 indicated that colorectal cancer (CRC) is the most common
malignant tumor of the digestive system, and that CRC ranked third in incidence rate and …
malignant tumor of the digestive system, and that CRC ranked third in incidence rate and …
[HTML][HTML] Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
X Zhang, T Wu, X Cai, J Dong, C Xia, Y Zhou… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence
and metastasis, although neoadjuvant therapy may provide some benefit. However, patients …
and metastasis, although neoadjuvant therapy may provide some benefit. However, patients …
Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
X Zhang, T Wu, X Cai, J Dong, C Xia, Y Zhou… - Frontiers in …, 2022 - europepmc.org
Patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence
and metastasis, although neoadjuvant therapy may provide some benefit. However, patients …
and metastasis, although neoadjuvant therapy may provide some benefit. However, patients …